Comparative Effectiveness and Safety of Ticagrelor and Clopidogrel in Patients With or Without Chronic Liver Disease: A Nationwide Cohort Study - 23/07/24
Abstract |
Background |
Although the effectiveness and safety of ticagrelor versus clopidogrel may differ in patients with chronic liver disease, there is a scarcity of evidence comparing ticagrelor and clopidogrel in patients with chronic liver disease. We aimed to evaluate the risk of major adverse cardiovascular events (MACE) and major bleeding associated with ticagrelor versus clopidogrel in patients undergoing percutaneous coronary intervention (PCI) due to acute coronary syndrome by chronic liver disease status.
Methods |
Using the Korean healthcare claim database, we included adult patients who underwent PCI and initiated ticagrelor or clopidogrel treatment within 7 days of an acute coronary syndrome diagnosis. Patients were classified into 2 mutually exclusive groups: patients with chronic liver disease and patients without chronic liver disease. Within each group, the hazard ratios (HRs) with 95% confidence intervals (CIs) of MACE and major bleeding associated with ticagrelor versus clopidogrel were calculated using a Cox proportional hazards model within a 1:1 propensity score (PS) matched cohort.
Results |
The final cohort included 14,261 and 148,535 patients with and without chronic liver disease, respectively. After PS matching, the risk of MACE (with chronic liver disease, HR: 1.01, 95% CI: 0.91-1.13; without chronic liver disease, HR: 1.02, 95% CI: 0.98-1.05; P for homogeneity: 0.865) and major bleeding (with chronic liver disease, HR: 1.07, 95% CI: 0.71-1.61; without chronic liver disease, HR: 1.32, 95% CI: 1.15-1.53; P for homogeneity: 0.342) for ticagrelor versus clopidogrel do not vary with chronic liver disease status.
Conclusions |
Among acute coronary syndrome patients undergoing PCI, the use of ticagrelor versus clopidogrel was associated with a similar risk of MACE and an increased risk of major bleeding, but these risks did not vary with chronic liver disease status.
Le texte complet de cet article est disponible en PDF.Keywords : Acute coronary syndrome, Ticagrelor, Clopidogrel, Chronic liver disease, Population-based cohort study
Plan
| Funding: This research was supported by a grant (21153MFDS607) from the Ministry of Food and Drug Safety, South Korea, in 2021-2025. This research was supported by a grant (22213MFDS486) from the Ministry of Food and Drug Safety, South Korea, in 2022. Dr. Bea was supported by the Health Fellowship Foundation (2022). |
|
| Conflicts of Interest: The authors declare no conflict of interests relevant to this study. Dr. Shin received grants from the Ministry of Food and Drug Safety, Ministry of Health and Welfare, National Research Foundation of Korea, and Government-wide R&D Fund for Infectious Disease Research and Pharmaceutical Companies, including Amgen, Pfizer, SK Bioscience, Daiichi Sankyo, and GSK. Dr. You servers as the Chief Technology Officer of PHI Digital Healthcare. No other relationships or activities have influenced the submitted work. |
|
| Authorship: BH: Conceptualization, Formal analysis, Investigation, Methodology, Visualization, Writing – original draft, Writing – review & editing. SB: Conceptualization, Investigation, Methodology, Writing – original draft, Writing – review & editing. SCY: Conceptualization, Investigation, Methodology, Writing – review & editing. YC: Conceptualization, Investigation, Methodology, Writing – review & editing. WK: Conceptualization, Investigation, Methodology, Writing – review & editing. J-YS: Conceptualization, Data curation, Funding acquisition, Investigation, Methodology, Supervision, Writing – review & editing. |
|
| Data sharing: No additional data are available to the public. |
Vol 137 - N° 8
P. 742 - août 2024 Retour au numéro
Article précédent
- Overall Medication Adherence as an Indicator for Health Outcomes Among Elderly Patients With Hypertension and Diabetes
- Michal Shani, Alex Lustman, Doron Comaneshter, Yochai Schonmann
- Characteristics and Outcomes of Hospitalized Patients With Heart Failure and Sarcoidosis: A Propensity-Matched Analysis of the Nationwide Readmissions Database 2010-2019
- Raheel Ahmed, Hiroyuki Sawatari, Khadija Amanullah, Joseph Okafor, Syed Emir Irfan Wafa, Saurabh Deshpande, Kamleshun Ramphul, Isma Ali, Mohammed Khanji, Sebastian Mactaggart, Omar Abou-Ezzeddine, Vasilis Kouranos, Rakesh Sharma, Virend K. Somers, Selma F. Mohammed, C. Anwar A. Chahal
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?